Agenda
| 9:00 AM - 9:30 AM |
Registration & Networking |
 |
| 9:30 AM - 10:30 AM |
Presentation & Q&A |
| 10:40 AM - 11:30 AM |
BioCenter Tour |
| 11:30 AM - 12:30 PM |
Lunch & Networking |
| 12:30 PM - 5:00 PM |
One-on-one Meetings |
Emerging companies find it increasingly difficult to reach the right person when seeking funding. It is equally difficult for funders to wade through countless proposals. The "Meet with" Series provides emerging life science companies with greater access to partnering and/or financing opportunities. The BioCenter Meet with Series has featured, Merck, Genentech, NCI, Takeda Research Investment, the Michael J. Fox Foundation, Physic Ventures and now Amgen!
In this session,
Amgen's External R&D Affairs team members will talk to potential licensees to first explain what they are looking for in a company. After the presentation, attendees will have lunch with the Amgen team.
Finally,
each pre-approved attendee* will be granted a private meeting with Amgen’s External R&D Affairs Executive Director
John O’Connor, or Licensing Manager
Tammy DeHahn,
Tom Storey, or
Martha Zambrano.
Currently, the
highest priorities for Amgen are in the following areas: Oncology/Hematology, Neuroscience, Bone Loss, Inflammation, Metabolism and Muscle, Nephrology, Discovery and Technology, Cardiovascular. However, the Amgen team might consider other areas of interest, so don't hesitate to apply!
*Registrations to one-on-one meetings are subject to approval of application. To apply, please send your Executive Summary by April 8, 2010 to events@sjbiocenter.com. The Review Board, composed of the BioCenter management team, sponsors, partners and mentors, will then meet to consider your application. You will be notified on April 13, 2010 if your application is accepted or rejected. Registration must be completed upon approval to secure your meeting slot.
Please visit our dedicated page for more information about the Meet with... Series»
One-on-one Meeting Application & Costs
• Application fee: FREE
• Registration for one company representative:
o $175 Regular
o $150 Partners’ Network
• Registration for two company representatives:
o $250 Regular
o $215 Partners’ Network
• Registration for three company representatives:
o $300 Regular
o $255 Partners’ Network
• Registration for four company representatives and above:
o add $40 [or $30 for Partners’ Network] per attendee
• BioCenter Residents and Affiliates: Free
Presentation & Q&A Costs**
• Regular Price: $40
• Partners' Network: $30
• BioCenter Members: Free (please RSVP to Aurélie)
**Includes: Presentation & Q&A session + lunch ONLY. Seating is limited for this event, so early pre-registration is recommended to avoid disappointment! Additionally, there will be no on-site registrations.
Venue
The San Jose BioCenter
5941 Optical Court
San Jose, CA 95138
Click here for venue directions»
About Amgen's areas of interest
Amgen is a leading human therapeutics company in the biotechnology industry. For more than 25 years, the company has tapped the power of scientific discovery and innovation to advance the practice of medicine.
Currently, the
highest priorities for Amgen are in the following areas:
- Oncology/Hematology
- Neuroscience
- Bone Loss
- Inflammation
- Metabolism and Muscle
- Nephrology
- Discovery and Technology
- Cardiovascular
However, the Amgen team might consider other areas of interest, so don't hesitate to apply!
Speakers Bios
John O’Connor, Executive Director, External R&D Affairs, Amgen Inc.
John O'Connor is Executive Director in Amgen's External R&D Affairs group responsible for Technology Licensing. John has been with Amgen for 14 years. John holds a BS degree in Biology from the University of Southern California and a JD degree from Loyola Law School of Los Angeles. Prior to Amgen, John practiced law at Skadden, Arps, Slate, Meagher & Flom, and prior to that worked in pharmaceutical research.
Tammy DeHahn, Licensing Manager, External R&D Affairs, Amgen Inc.
Tammy is a Licensing Manager in External R&D Affairs at Amgen. Tammy is a part of the Inflammation Product Licensing team, whose responsibilities include identifying and assessing new opportunities and determining the best business structure to establish a partnership, including licensing agreements, collaboration agreements and acquisitions. She has thirteen years of experience in the pharmaceutical and biotech industries, in the areas of oncology research, intellectual property, and licensing. Tammy received her Master of Science degree in Plant Physiology/Biochemistry from Purdue University and her Bachelor of Science degree in Biology from Indiana University.
Tom Storey, Licensing Manager, External R&D Affairs, Amgen Inc.
Tom is a Licensing Manager in Business Development at Amgen where he is responsible for identifying and leading scientific diligence on licensing and acquisition opportunities in metabolic disorders, nephrology, and neuroscience. Tom holds an MBS from Keck Graduate Institute of Applied Life Sciences and an MBA from ULCA Anderson School of Management.
Martha Zambrano, Licensing Manager, External R&D Affairs, Amgen Inc.
Martha Zambrano is a Manager in the Business Development Department at Amgen. Martha’s responsibilities include sourcing, evaluating, and in-licensing research technologies in the areas of protein sciences, process sciences, metabolic disorders, oncology, PKDM and drug delivery While at Amgen, Martha has developed strategic collaborations with academic institutions and companies worldwide. Prior to joining Amgen’s licensing group in 2000, Martha worked in the metabolic disorders group at Amgen. Martha holds a BS in Biology from UCSB and an MBA from Pepperdine.
